Technology | January 27, 2011

FDA Expands LifeStent Use to Longer SFA Lesions


January 27, 2010 – The U.S. Food and Drug Administration (FDA) expanded the indication for the Bard Peripheral Vascular LifeStent and LifeStent XL nitinol self-expanding stents for the treatment of lesions up 240 mm in length.

The stents are now indicated are intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in native superficial femoral artery (SFA) and/or proximal popliteal arteries with reference vessel diameters ranging from 4 to 6.5 mm.

The stents were originally cleared in February 2009 for the treatment of lesions up to 160 mm in length. The stents are equivalent in design with only one difference located at the crown section. The LifeStent stent has six tantalum radiopaque markers on both the distal and proximal ends of the stent, while the LifeStent XL stent does not have markers.

The expanded indication was granted in December 2010.

For more information: www.bardpv.com

Related Content

Feature | Stents Peripheral | Dave Fornell, Editor

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

Home November 06, 2019
Home
Technology | Stents Peripheral

October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System ...

Home October 05, 2018
Home
News | Stents Peripheral

April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million. This financing is ...

Home April 27, 2018
Home
News | Stents Peripheral

July 26, 2017 — Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home July 26, 2017
Home
News | Stents Peripheral

July 14, 2017 — Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational ...

Home July 14, 2017
Home
News | Stents Peripheral

April 28, 2017 — Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting ...

Home April 28, 2017
Home
News | Stents Peripheral

March 16, 2017 — W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular ...

Home March 16, 2017
Home
News | Stents Peripheral

March 2, 2017 — Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home March 02, 2017
Home
News | Stents Peripheral

December 13, 2016 — Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal ...

Home December 13, 2016
Home
News | Stents Peripheral

December 8, 2016 — LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow ...

Home December 08, 2016
Home
Subscribe Now